119 related articles for article (PubMed ID: 28623006)
21. An HPLC tracing of the enhancer regulation in selected discrete brain areas of food-deprived rats.
Miklya I; Knoll B; Knoll J
Life Sci; 2003 May; 72(25):2923-30. PubMed ID: 12697275
[TBL] [Abstract][Full Text] [Related]
22. Essential difference between the pharmacological spectrum of (-)-deprenyl and rasagiline.
Miklya I
Pharmacol Rep; 2014 Jun; 66(3):453-8. PubMed ID: 24905523
[TBL] [Abstract][Full Text] [Related]
23. Metabolic transformation plays a primary role in the psychostimulant-like discriminative-stimulus effects of selegiline [(R)-(-)-deprenyl].
Yasar S; Justinova Z; Lee SH; Stefanski R; Goldberg SR; Tanda G
J Pharmacol Exp Ther; 2006 Apr; 317(1):387-94. PubMed ID: 16352699
[TBL] [Abstract][Full Text] [Related]
24. Analysis of the effect of (-)-BPAP, a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain.
Miklya I; Knoll J
Life Sci; 2003 May; 72(25):2915-21. PubMed ID: 12697274
[TBL] [Abstract][Full Text] [Related]
25. (-)Deprenyl (Selegiline): past, present and future.
Knoll J
Neurobiology (Bp); 2000; 8(2):179-99. PubMed ID: 11061214
[TBL] [Abstract][Full Text] [Related]
26. Sexual performance and longevity.
Knoll J
Exp Gerontol; 1997; 32(4-5):539-52. PubMed ID: 9315455
[TBL] [Abstract][Full Text] [Related]
27. [Possible mechanism of selective inhibition of rat liver mitochondrial monoamine oxidase by chlorgiline and deprenyl].
Severina IS
Biokhimiia; 1979 Feb; 44(2):195-207. PubMed ID: 435561
[TBL] [Abstract][Full Text] [Related]
28. Chronic treatment with enhancer drugs modifies the gene expression of selected parameters related to brain plasticity in rats under stress conditions.
Hrivikova K; Zelena D; Graban J; Puhova A; Miklya I; Balazsfi D; Jezova D
Neurochem Int; 2022 Oct; 159():105404. PubMed ID: 35853552
[TBL] [Abstract][Full Text] [Related]
29. (-)Deprenyl and (-)1-phenyl-2-propylaminopentane, [(-)PPAP], act primarily as potent stimulants of action potential-transmitter release coupling in the catecholaminergic neurons.
Knoll J; Miklya I; Knoll B; Markó R; Kelemen K
Life Sci; 1996; 58(10):817-27. PubMed ID: 8602114
[TBL] [Abstract][Full Text] [Related]
30. Antiaging compounds: (-)deprenyl (selegeline) and (-)1-(benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective highly potent enhancer of the impulse propagation mediated release of catecholamine and serotonin in the brain.
Knoll J
CNS Drug Rev; 2001; 7(3):317-45. PubMed ID: 11607046
[TBL] [Abstract][Full Text] [Related]
31. Acute effects of moclobemide and deprenyl on 5-HT synthesis rates in the rat brain: An autoradiographic study.
Nishi K; Mück-Seler D; Hasegawa S; Watanabe A; Diksic M
Brain Res Bull; 2006 Oct; 70(4-6):368-77. PubMed ID: 17027772
[TBL] [Abstract][Full Text] [Related]
32. Comparison of behavioral effects of moclobemide and deprenyl during forced swimming.
Ferigolo M; Barros HM; Marquardt AR; Tannhauser M
Pharmacol Biochem Behav; 1998 Jun; 60(2):431-7. PubMed ID: 9632226
[TBL] [Abstract][Full Text] [Related]
33. Effect of (-)-para-fluoro-deprenyl on survival and copulation in male rats.
Dalló J; Knoll J
Acta Physiol Hung; 1992; 79(2):125-9. PubMed ID: 1304678
[TBL] [Abstract][Full Text] [Related]
34. [The feasibility of synthetic enhancer substances for preventive nanotherapy].
Miklya I
Neuropsychopharmacol Hung; 2010 Sep; 12(3):395-403. PubMed ID: 20962359
[TBL] [Abstract][Full Text] [Related]
35. Rationale for (-)deprenyl (selegiline) medication in Parkinson's disease and in prevention of age-related nigral changes.
Knoll J
Biomed Pharmacother; 1995; 49(4):187-95. PubMed ID: 7669938
[TBL] [Abstract][Full Text] [Related]
36. (-)-Trans-epsilon-viniferin, a polyphenol present in wines, is an inhibitor of noradrenaline and 5-hydroxytryptamine uptake and of monoamine oxidase activity.
Yáñez M; Fraiz N; Cano E; Orallo F
Eur J Pharmacol; 2006 Aug; 542(1-3):54-60. PubMed ID: 16828740
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of monoamine oxidase isoforms modulates nicotine withdrawal syndrome in the rat.
Malin DH; Moon WD; Goyarzu P; Barclay E; Magallanes N; Vela AJ; Negrete AP; Mathews H; Stephens B; Mills WR
Life Sci; 2013 Oct; 93(12-14):448-53. PubMed ID: 23988853
[TBL] [Abstract][Full Text] [Related]
38. Phenylethylamine-induced stereotypies in the rat: a behavioral test system for assessment of MAO-B inhibitors.
Ortmann R; Schaub M; Felner A; Lauber J; Christen P; Waldmeier PC
Psychopharmacology (Berl); 1984; 84(1):22-7. PubMed ID: 6436886
[TBL] [Abstract][Full Text] [Related]
39. Selegiline long-term effects on brain acetylcholinesterase, (Na+,K+)-ATPase activities, antioxidant status and learning performance of aged rats.
Carageorgiou H; Zarros A; Tsakiris S
Pharmacol Res; 2003 Sep; 48(3):245-51. PubMed ID: 12860442
[TBL] [Abstract][Full Text] [Related]
40. Effects of (R)-(-)-1-(benzofuran-2-yl)-2-propylaminopentane hydrochloride [(-)-BPAP] in animal models of mood disorders.
Tsunekawa H; Noda Y; Miyazaki M; Yoneda F; Nabeshima T; Wang D
Behav Brain Res; 2008 May; 189(1):107-16. PubMed ID: 18243357
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
